Avita Medical Ltd., a Valencia company that makes regenerative treatments for wounds and skin defects, has filed a petition against a patent owned by competitor New York-based Renovacare Sciences Corp. Avita develops treatments that utilize a small sample of a patient’s own skin cells, which are then broken up and mixed into a solution to help them multiply. Then, the solution is sprayed onto a burned or injured area to promote healthy skin growth. Currently, its ReCell therapy technology is commercially available. Renovacare is currently developing its early-stage stem cell technology, which also involves spraying the patient’s own skin cells on a burn wound. Its therapy, known as the CellMist system, is not currently on the market, but the company holds U.S. patent No. 9,610,430 to protect some of its technology, which Avita claims infringes on its intellectual property. Avita filed the patent challenge with the U.S. Patent Trial and Appeal Board (PTAB), which will review the petition to decide if the case should go to trial. “We believe we have presented a very strong rationale to the PTAB as to why this patent should never have been issued, and thus, we respectfully request that all claims in the ‘430 patent should be cancelled,” Avita Chief Executive Adam Kelliher said in a statement. “Avita is a pioneer in the regenerative medicine arena, and we are very protective of our intellectual property rights.” Avita (AVMXY) shares closed up 1 cent, or less than a percent, to $1.38 on the over-the-counter market.